Rated 4.8 · Verified patient reviewsWegovy injections for weight loss
A once-weekly injection pen with semaglutide, prescribed only after a UK clinician reviews your health.
- In a 68 weeks study, people on the highest dose lost up to 14.9% of their body weight
- From £139 a month
Takes about two minutes · cancel any time

- UK-registered pharmacy, dispensed in the UK
- Prescribed only after a clinician review
- Free weekday next-day delivery in discreet packaging
Dosing
Dosing Schedule
6 strengths, one step at a time. From £139 a month, everything included.
Starting dose

0.25mg
Weeks 1 to 4
£139a month
Step up

0.5mg
Weeks 5 to 8
£179a month

1mg
Weeks 9 to 12
£187a month

1.7mg
Weeks 13 to 16 or longer
£237a month
Maintenance

2.4mg
Week 17 onwards
£287a month

7.2mg
Week 21 onwards
£328a month
What is Wegovy?
Wegovy is a once-weekly injection licensed for weight management. The active ingredient is semaglutide. It works on the GLP-1 appetite hormone pathway, the same pathway targeted by other established weight-loss medicines.
By copying that signal it helps steady appetite, slow digestion and improve blood sugar control. It has the longest real-world track record of the weekly injections currently available in the UK.
In a 68-week study people on the highest dose lost an average of 14.9% of their body weight when semaglutide was combined with lifestyle support.
How it works
How Wegovy works
Clinician-led treatment works with the body's own appetite signals rather than against them, which is why the weight tends to stay off while you are on it.
Quieter appetite
You feel less pulled towards food between meals, so choices get easier.
Fuller for longer
Your stomach empties more slowly, so smaller meals still satisfy.
Fewer cravings
The constant background thinking about food tends to settle down.
Steadier blood sugar
Fewer energy dips through the day, which means fewer hunger spikes.
One pathway
GLP-1
Wegovy copies one hormone pathway. It is the same pathway used by other established weight-loss medicines, and the one with the longest real-world safety record in the UK.
GLP-1
Slows stomach emptying, helping you feel fuller for longer
Reduces appetite and the drive to eat
Helps reduce food cravings and snacking
Helps control the rise in blood sugar after eating
Wegovy vs Mounjaro for weight loss
Both are weekly injections and both quiet appetite. The difference is how many gut hormone pathways each one copies — semaglutide copies one, tirzepatide copies two — and that gap shows up in the trial figures.

Wegovy
Semaglutide · GLP-1 only
The established single-pathway option

Mounjaro
Tirzepatide · GLP-1 + GIP
The dual-pathway option, higher average loss
Average weight loss in trials
14.9% at 2.4mg
20.9% at 15mg
Hormone pathways copied
One — GLP-1
Two — GLP-1 and GIP
What the second pathway adds
Not applicable
GIP appears to improve how the body handles fat and blood sugar alongside appetite
Higher-dose option
2.4mg standard, 7.2mg prescriber-led
15mg is the top licensed dose
Typical tolerance settling in
Often settles more easily for people sensitive to nausea
More loss, but dose increases can be harder to tolerate
Track record in the UK
Longer real-world use, larger body of published data
Newer, with strong trial data from 2022 onwards
Using it
How do you use the Wegovy pen?
A dial-a-dose FlexTouch pen with a new needle each week, four doses per pen. Three stages, start to finish.
Keep unopened pens in the fridge between 2 and 8 degrees. Once you have started a pen, keep it for up to 6 weeks, in the fridge or below 30 degrees, with the cap on. Never freeze it.
Read the patient information leafletSafety
Common side effects for Wegovy?
Side effects are common when you start any new medicine. Most are mild and ease off as your body settles, and going up more slowly helps more than anything else.
Like all medicines, Wegovy has side effects. In the STEP trials, nausea, diarrhoea and constipation were common. They were usually mild, worst in the first week after a dose increase, and faded within a few days as the body settled.
The most common Wegovy side effects include
- Headache
- Feeling sick
- Being sick
- Diarrhoea
- Constipation
- Tummy pain
- Feeling weak or tired
These are usually worst in the first week after a dose increase and settle within a few days. Going up more slowly helps more than anything else.
We will not prescribe it if
- You are pregnant, breastfeeding or trying to conceive
- You have had medullary thyroid cancer or MEN 2
- You have had pancreatitis
- You are already taking another GLP-1 medicine
Not sure if a side effect is normal?
Message the clinical team on WhatsApp, seven days a week. We can tell you what needs attention and what usually settles on its own.
Message your clinical team
A clinician in your pocket, 7 days a week
Ask a question on WhatsAppCancel anytime · No lock-in · No consultation fee

ClariDay Clinical Team
online
Your projection
See what 14.9% weight loss looks like for you
Put in your details to see a personalised trajectory over 68 weeks, based on Wegovy trial outcomes.
Questions
The things people actually ask
Do you put weight back on after stopping Wegovy?
Most people regain some weight after stopping. In STEP 1, participants who stopped treatment began to regain weight, and appetite returns as the medicine clears. Obesity is a long-term condition, so weight tends to return once the medicine stops unless eating patterns, activity and sleep have changed alongside it. Stopping is usually best planned with a prescriber.
How long does Wegovy take to work?
Appetite usually changes within the first one to two weeks, often before any change on the scales. Weight loss typically becomes clear from around the third month, and in the trials it continued steadily for about 68 weeks before levelling off. The rate of loss depends on dose, starting weight, diet and activity.
How much weight can you lose on Wegovy?
Average weight loss was 14.9% of body weight over 68 weeks on the 2.4mg dose in the STEP 1 trial, against 2.4% on placebo, all alongside diet and exercise support. Around eight in ten participants lost at least 5% of their starting weight. Individual results vary widely, and no outcome can be guaranteed.
Do you lose muscle on Wegovy?
Some lean tissue is lost with any substantial weight loss, typically a minority of the total. Loss is reduced by eating enough protein at each meal, generally around 1.2 to 1.6g per kilogram of body weight per day, and by resistance training two or three times a week. Preserving muscle helps maintain strength, mobility and resting energy expenditure.
What is the difference between Wegovy and Mounjaro?
Both are once-weekly injections licensed in the UK for weight management, but they act differently. Wegovy (semaglutide) acts on one hormone pathway, GLP-1, while Mounjaro (tirzepatide) acts on GLP-1 and GIP. Average trial weight loss is higher with tirzepatide, at around 20.9% over 72 weeks against about 14.9% for semaglutide over 68 weeks. Wegovy has a longer real-world track record in the UK. The right choice depends on medical history, tolerance and clinical judgement.
Is Wegovy the same as Ozempic?
They contain the same active ingredient, semaglutide, but they are licensed for different things. Ozempic is licensed in the UK for type 2 diabetes, while Wegovy is licensed for weight management. Doses and pens can differ, so they are not interchangeable.
References (5)
- 1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
- 2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in people with overweight or obesity (SELECT). N Engl J Med. 2023;389(16):1391-1402.
- 3. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effect of semaglutide 2.4mg on weight control in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091.
- 4. Wegovy solution for injection in pre-filled pen. Summary of Product Characteristics, electronic medicines compendium.
- 5. Wegovy 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg FlexTouch pre-filled pen. Patient information leaflet, Novo Nordisk Limited, electronic medicines compendium (pil.13799).
Authored by · 18 August 2026
Ali Salih — MPharm
Prescribing pharmacist
GPhC 2212755
Reviewed by · 18 August 2026
Dr A Ameer
Clinical pharmacist, medical review
UK-registered healthcare professional
Begin your clinical assessment today
Prescription, clinician review and pharmacy delivery included. You only pay if our clinicians approve your treatment.
No charge unless our clinicians approve your treatment

Wegovy · 0.25mg
from £139 a month


